GMAB News and Press, Genmab A/S From 02/01/23

Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...

Summary Genmab (GMAB) is a Danish commercial biopharma company with a leading technology and track record in innovative antibody-based therapeutics. Darzalex royalty revenue is the key driver of the stock price and the bedrock of Genmab's strong performance during 2021-2022. We expe...

Company Announcement Net sales of DARZALEX ® in 2022 totaled USD 7, 977 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc . (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof. ...

Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...

Genmab ( GMAB ) ( GMXAY ) ( OTCPK:GNMSF ) submitted a new drug application (NDA) to Japan's Ministry of Health, Labor and Welfare (MHLW) for subcutaneous epcoritamab (DuoBody-CD3xCD20) to treat patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who had ...

Genmab A/S (Nasdaq: GMAB): JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkin’s lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S ...

Citi has downgraded Genmab ( GMAB ) to neutral from buy citing foreign exchange rates and potential delays for two pipeline assets. The firm has a DKR3055 price target (~1% upside based on Tuesday's close on the Nasdaq Nordic). Analyst Peter Verdult said that a next phase go/no-go dec...

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell l...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 ...